Eli Lilly: first trials on an antibody against Covid

(CercleFinance.com) - The American biopharmaceutical group Eli Lilly said on Monday that it has started the first clinical trials on a therapeutic antibody designed to neutralise the Covid-19 virus.


In a statement, Lilly said that the first patients in New York and Los Angeles have received this experimental treatment in Phase 1 clinical trials, the first results of which are set to be announced by the end of the month.

Phase II trials should then begin to assess the treatment's effectiveness in the most vulnerable patients.

The antibody - named "LY-CoV555" - was identified in collaboration with the Canadian biotech group AbCellera from a blood sample from one of the first US coronavirus patients to be cured of the disease.

Eli Lilly also announced on Monday that its drug Taltz - a humanized immunoglobulin - has been approved by the US FDA for the treatment of non-radiographic axial spondylitis (nr-axSpA).


Copyright (c) 2020 CercleFinance.com. All rights reserved.